Gilead honors Camber parent company Hetero Drugs

PISCATAWAY, N.J. — Camber Pharmaceuticals announced Wednesday that its parent company, Hetero Drugs, has been recognized by Gilead Sciences for its work providing access to hepatitis C drugs for patients worldwide. Hetero markets sofosbuvir  as Sofovir and ledipasvir-sofosbuvir as Ledifos in India and will eventually reach some 91 countries. The two drugs are better known in the United States and as Sovaldi and Harvoni. 

 

In India, an estimated 12 million to 18 million patients are infected with hepatitis C. 

 

“We are proud that Hetero has received recognition from such an innovative and respected organization as Gilead Sciences,” Camber president Kon Ostaficiuk said. “Hetero and Camber’s core mission has always been to provide cost-effective medications to as many patients as possible.”